NCT02912949: An ongoing trial by Partner Therapeutics, Inc.
This trial is ongoing. It must report results 2 years from now.
Full data
| Full entry on ClinicalTrials.gov | NCT02912949 |
|---|---|
| Title | A Phase I/II Study of MCLA-128, a Full Length IgG1 Bispecific Antibody Targeting HER2 and HER3, in Patients With Solid Tumors (eNRGy) |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Jan. 31, 2015 |
| Completion date | Dec. 31, 2026 |
| Required reporting date | Dec. 31, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |